144 related articles for article (PubMed ID: 12771302)
21. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
22. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
Murakami K; Miyachi H; Watanabe A; Kawamura N; Fujii M; Koide S; Murase M; Kushimoto H; Hasegawa M; Tomita M; Hiki Y; Sugiyama S
Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
Tamura S; Ueki K; Mashimo K; Tsukada Y; Naitoh M; Abe Y; Kawai H; Tsuchida A; Wakamatsu R; Nojima Y
Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
25. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
[TBL] [Abstract][Full Text] [Related]
27. Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism.
Douthat WG; Orozco SE; Maino P; Cardozo G; de Arteaga J; de la Fuente J; Chiurchiu CR; Massari PU
Transpl Int; 2007 Dec; 20(12):1031-5. PubMed ID: 17883371
[TBL] [Abstract][Full Text] [Related]
28. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
[TBL] [Abstract][Full Text] [Related]
29. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
30. [Percutaneous ethanol injections in the treatment of secondary hyperparathyroidism].
Kuzdak K; Rybińska A; Białas M
Endokrynol Pol; 2005; 56(6):891-6. PubMed ID: 16821207
[TBL] [Abstract][Full Text] [Related]
31. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol.
Gallieni M; Brancaccio D; Padovese P; Rolla D; Bedani P; Colantonio G; Bronzieri C; Bagni B; Tarolo G
Kidney Int; 1992 Nov; 42(5):1191-8. PubMed ID: 1453603
[TBL] [Abstract][Full Text] [Related]
32. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism.
Nakanishi S; Yano S; Nomura R; Tsukamoto T; Shimizu Y; Shin J; Fukagawa M
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii47-9. PubMed ID: 12771300
[TBL] [Abstract][Full Text] [Related]
34. Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients.
Barton Pai A; Lin S; Arruda JA; Lau AH
Int J Artif Organs; 2003 Jun; 26(6):484-90. PubMed ID: 12866654
[TBL] [Abstract][Full Text] [Related]
35. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
36. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
37. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
38. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.
Akizawa T; Ohashi Y; Akiba T; Suzuki M; Nishizawa Y; Ogata E; Slatopolsky E; Kurokawa K
Ther Apher Dial; 2004 Dec; 8(6):480-91. PubMed ID: 15663548
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol.
Sprague SM; Moe SM
Am J Kidney Dis; 1992 Jun; 19(6):532-9. PubMed ID: 1595701
[TBL] [Abstract][Full Text] [Related]
40. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients.
Kakuta T; Kunimatsu K; Tadaki F; Fujisaki T; Noguchi M; Abe Y; Sakai H; Kurokawa K; Saito A
Biomed Pharmacother; 2000 Jun; 54 Suppl 1():60s-65s. PubMed ID: 10914993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
